CD274 and neoplasm: Some studies have reported that sunitinib can improve the antitumor effect of anti-DR5 receptor immunotherapy by normalizing tumor vasculature, improving lymphatic system function, and increasing CD8+ T cell infiltration (125); some recent studies have indicated that sunitinib can reduce PD-L1 expression by regulating P62, thus improving CTL activity and immunotherapeutic efficacy (126).